Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

Dispelling the Myriad gene patent harmonization myth

Foley & Lardner LLP
-
Australia, Canada, European Union, France, Germany, Japan, USA
-
April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Ban on embryonic stem cell patenting in Europe Court of Justice rules on meaning of "human embryo" in stem cells debate

Hogan Lovells
-
European Union, Germany
-
October 25 2011

The Court of Justice of the European Union (CJEU) handed down its long-awaited judgment in the Brüstle case on the patentability of stem cell inventions

German Supreme Court finally finds patent on embryonic stem cell technology valid under reasonable terms while the position of the EPO is still open

Prüfer & Partner GbR
-
European Union, Germany
-
February 1 2013

Following the preliminary ruling of the Court of Justice of the European Union (CJEU; case C-3410), the long awaited final decision of the German

FSC decides on patentability of neural progenitor cells II (Brustle)

Bird & Bird
-
Germany
-
February 25 2013

Recently, the German Federal Supreme Court decided on a nullity action on the patentability of progenitor cells extracted from human embryonic stem

Denial of absolute product protection for DNA-patents (CJ decision in Monsanto v Cefetra, C- 42808) a German perspective

Bird & Bird
-
European Union, Germany
-
July 27 2010

The Court of Justice of the European Communities just recently denied absolute product protection of patent claims directed to DNA sequences in the case Monsanto v Cefetra and others, C- 42808

Stem cells confirmed too potent to patent in EU

Shepherd & Wedderburn LLP
-
European Union, Germany
-
November 18 2011

On 10 March 2011, Advocate General Bot delivered his opinion in relation to Case C-3410, a reference to the Court of Justice of the European Union (CJEU) from the German Federal Court of Justice (Bundesgerichtshof) in Oliver Brüstle v Greenpeace eV

Patent victory in preliminary injunction proceeding in Germany

Quinn Emanuel Urquhart & Sullivan LLP
-
Germany
-
January 8 2012

The firm recently secured denial of a preliminary injunction against its client, Servona GmbH (“Servona”), a leading supplier of medical products in Germany

Patent term extension for medical devices: new opportunities, open questions

Jones Day
-
Germany
-
February 15 2011

The first German patent term extension granted for a medical device, a combination product, may open the door for extended patent protection for combination products

Drug patents in the EU: up to 15 years and six months’ protection from marketing authorization

Squire Sanders Hammonds
-
European Union, Germany
-
August 16 2011

The German Federal Patent Court requested that the Court of Justice of the European Union (the Court) provide a ruling as to whether a Supplementary Protection Certificate (SPC) may be granted if it would not result in a “positive” term, because marketing authorization (APM) for a drug had been obtained within five years of the filing of the corresponding patent application

Court of Justice clarifies exclusion against patenting of embryonic stem cells

CMS Cameron McKenna
-
European Union, Germany
-
October 26 2011

Under Article 5 of EU Directive 9844EC the “Biotech Directive”, the human body, at the various stages of its formation and development, and the simple discovery of one of its elements, including the sequence or partial sequence of a gene, cannot constitute patentable inventions

next >

Search results

Dispelling the Myriad gene patent harmonization myth

Ban on embryonic stem cell patenting in Europe Court of Justice rules on meaning of "human embryo" in stem cells debate

German Supreme Court finally finds patent on embryonic stem cell technology valid under reasonable terms while the position of the EPO is still open

FSC decides on patentability of neural progenitor cells II (Brustle)

Denial of absolute product protection for DNA-patents (CJ decision in Monsanto v Cefetra, C- 42808) a German perspective

Stem cells confirmed too potent to patent in EU

Patent victory in preliminary injunction proceeding in Germany

Patent term extension for medical devices: new opportunities, open questions

Drug patents in the EU: up to 15 years and six months’ protection from marketing authorization

Court of Justice clarifies exclusion against patenting of embryonic stem cells

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction